We highlighted the potential of miR- 132-5p, miR-132-3p, miR-124-3p, and miR-133a-3p expression levels in plasma as biomarkers of preclinical progression for G376D-TARDBP-associated ALS. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.